An engineered ACE2 decoy receptor can be administered by inhalation and potently targets the BA.1 and BA.2 omicron variants of SARS-CoV-2

Lianghui Zhang(Illinois College), Erik Procko(University of Illinois Urbana-Champaign)
bioRxiv (Cold Spring Harbor Laboratory)
March 28, 2022
Cited by 22


Related Papers